Print page  |  Text size: A  A  A
This site is intended for U.S. Healthcare Professionals only.

Provide a Simple-To-Use,
Effective Hormone Therapy
With CombiPatch®

Request Samples of CombiPatch

CombiPatch - a discreet transdermal patch indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe vulvar and vaginal atrophy in postmenopausal women with an intact uterus.

Please see Important Safety Information below, including Boxed WARNING, and link to Full Prescribing Information.

Two Discreet
Dosing Options

CombiPatch 0.05/0.25 mg per day

CombiPatch 0.05/0.14 mg per day

Patches are not shown actual size.

Transdermal Delivery Avoids 1st-Pass Metabolism

CombiPatch continuously releases estrogen via skin into the bloodstream, therefore avoiding first-pass liver metabolism, thus achieving effective hormone levels with smaller total doses compared to oral estrogen in pills.1 This does not imply differences in safety or efficacy with other hormone therapies.

Keep Pace With Busy Lifestyles

CombiPatch has been shown to have a low level of skin irritation. The patch is designed to stay on as your patients go about their daily activities, even when bathing, swimming, or exercising.1

2 Dosing Regimens + 2 Dosing Options = A Patch Designed With Choice in Mind

CombiPatch enables you to respond to the needs of individual patients with a choice of 2 dosing options (0.05/0.25 or 0.05/0.14 mg/day) and 2 FDA-approved regimens:

Continuous Combined Regimen:

  • Significantly reduces moderate to severe hot flashes as well as vulvar and vaginal atrophy

  • Helps to achieve amenorrhea

  • Patients should be educated about the possibility of breakthrough bleeding1

Continuous Sequential Regimen:

  • Significantly reduces moderate to severe hot flashes as well as vulvar and vaginal atrophy

  • Helps achieve a predictable monthly bleed

  • Patients should be educated that monthly withdrawal bleeding often occurs1


CombiPatch® (estradiol/norethindrone acetate transdermal system) is indicated for women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause, and moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. CombiPatch is also indicated for treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.


Estrogens and progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive pulmonary emboli (PE), and deep vein thrombosis (DVT) in postmenopausal women.

The Women's Health Initiative Memory Study (WHIMS), reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older.

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.

In the absence of comparable data, these risks should be assumed to be similar for all doses and dosage forms of estrogen and progestin containing products. Because of these risks, estrogens with progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

CombiPatch should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, arterial thromboembolic disease, or history of these conditions; liver dysfunction or disease; known anaphylactic reaction or angioedema or hypersensitivity to CombiPatch; known protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders or known or suspected pregnancy.

Estrogen increases the risk of gallbladder disease. Discontinue estrogen plus progestin if severe hypercalcemia, vision abnormalities, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy.

In clinical trials with CombiPatch, the most common side effects were breast pain, dysmenorrhea, and headache.

These are not all the side effects of CombiPatch.

Click here to read the Full Prescribing Information, including Boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Reference: 1. CombiPatch [Prescribing Information]. Miami FL: Noven Therapeutics, LLC; 2017.

Close X
Leaving the CombiPatch® Web Site

You are now leaving the CombiPatch Web site and moving to an external Web site independently operated and not managed by Noven Pharmaceuticals. Noven assumes no responsibility for the content of the site.